JPWO2021220183A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021220183A5 JPWO2021220183A5 JP2022566012A JP2022566012A JPWO2021220183A5 JP WO2021220183 A5 JPWO2021220183 A5 JP WO2021220183A5 JP 2022566012 A JP2022566012 A JP 2022566012A JP 2022566012 A JP2022566012 A JP 2022566012A JP WO2021220183 A5 JPWO2021220183 A5 JP WO2021220183A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cycloalkyl
- unsubstituted
- substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 90
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000001153 fluoro group Chemical group F* 0.000 claims description 33
- 102000013691 Interleukin-17 Human genes 0.000 claims description 26
- 108050003558 Interleukin-17 Proteins 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 230000002757 inflammatory effect Effects 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 26
- 208000011580 syndromic disease Diseases 0.000 claims description 26
- -1 1H-pyrazolyl Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000002557 hidradenitis Diseases 0.000 claims description 3
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 238000000034 method Methods 0.000 description 21
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 2
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 2
- 125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 1
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017679P | 2020-04-30 | 2020-04-30 | |
| US63/017,679 | 2020-04-30 | ||
| PCT/IB2021/053517 WO2021220183A1 (en) | 2020-04-30 | 2021-04-28 | Imidazopyrimidines as modulators of il-17 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023523770A JP2023523770A (ja) | 2023-06-07 |
| JP2023523770A5 JP2023523770A5 (https=) | 2024-04-15 |
| JPWO2021220183A5 true JPWO2021220183A5 (https=) | 2024-04-15 |
| JP7661361B2 JP7661361B2 (ja) | 2025-04-14 |
Family
ID=75769661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566012A Active JP7661361B2 (ja) | 2020-04-30 | 2021-04-28 | Ｉｌ－１７のモジュレーターとしてのイミダゾピリミジン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559496B2 (https=) |
| EP (1) | EP4143193B1 (https=) |
| JP (1) | JP7661361B2 (https=) |
| KR (1) | KR20230018387A (https=) |
| CN (1) | CN115867348B (https=) |
| AU (1) | AU2021262588A1 (https=) |
| BR (1) | BR112022021957A2 (https=) |
| CA (1) | CA3181793A1 (https=) |
| IL (1) | IL297734A (https=) |
| MX (1) | MX2022013650A (https=) |
| WO (1) | WO2021220183A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284283B2 (en) * | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| US10152431B2 (en) | 2015-03-16 | 2018-12-11 | Honeywell International Inc. | System and method for remote set-up and adjustment of peripherals |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2019138017A1 (en) * | 2018-01-15 | 2019-07-18 | Ucb Biopharma Sprl | Fused imidazole derivatives as il-17 modulators |
| WO2019223718A1 (zh) | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| IL279348B2 (en) * | 2018-06-15 | 2026-01-01 | Reata Pharmaceuticals Inc | Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma |
| JP7349491B2 (ja) * | 2018-07-12 | 2023-09-22 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体 |
| KR20230019507A (ko) * | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| MX2022013649A (es) | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Métodos para identificar moduladores de la ruta de il-17. |
-
2021
- 2021-04-28 WO PCT/IB2021/053517 patent/WO2021220183A1/en not_active Ceased
- 2021-04-28 US US17/997,437 patent/US12559496B2/en active Active
- 2021-04-28 IL IL297734A patent/IL297734A/en unknown
- 2021-04-28 CA CA3181793A patent/CA3181793A1/en active Pending
- 2021-04-28 AU AU2021262588A patent/AU2021262588A1/en not_active Abandoned
- 2021-04-28 MX MX2022013650A patent/MX2022013650A/es unknown
- 2021-04-28 JP JP2022566012A patent/JP7661361B2/ja active Active
- 2021-04-28 BR BR112022021957A patent/BR112022021957A2/pt not_active Application Discontinuation
- 2021-04-28 CN CN202180047235.4A patent/CN115867348B/zh active Active
- 2021-04-28 EP EP21723010.1A patent/EP4143193B1/en active Active
- 2021-04-28 KR KR1020227041944A patent/KR20230018387A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69431056T2 (de) | Substituierte oxazolyl-derivate zur behandlung von entzündungen | |
| TWI393564B (zh) | 新穎二唑衍生物、其醫藥組成物及其用途 | |
| JP3110467B2 (ja) | キノキサリンジオン類 | |
| JP2002525358A (ja) | ベンズアミド誘導体及びサイトカイン阻害剤としてのその使用 | |
| JP2000513024A (ja) | 抗炎症性ピペラジニルベンジルテトラゾール誘導体とその中間体 | |
| JPH09505829A (ja) | 炎症および炎症関連障害を処置するための１，４，５−トリフェニルピラゾリル化合物 | |
| JPH10503201A (ja) | 炎症治療用３，４−置換ピラゾール | |
| JP2006519818A (ja) | ロフルミラストの新規の製造方法 | |
| IL111002A (en) | Piperidine derivatives their preparation and pharmaceutical compositions containing them | |
| GB2474748A (en) | 5-Biphenylisoxazole derivatives as lysophosphatidic acid receptor antagonists | |
| JPWO2021220183A5 (https=) | ||
| FR2613720A1 (fr) | Derives d'aryl-heteroaryl carbinols avec activite analgesique | |
| JPS5965036A (ja) | アラキドン酸類縁体、その製法および医薬用途 | |
| JP2003513961A (ja) | シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物 | |
| JPWO2019160057A5 (https=) | ||
| WO2014200075A1 (ja) | ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| JPH07502022A (ja) | トリアゾール抗真菌剤 | |
| JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| KR860001879B1 (ko) | 폴리프레닐 화합물의 제조방법 | |
| JPH05502454A (ja) | 抗ムスカリン性気管支拡張剤 | |
| JPWO2023049887A5 (https=) | ||
| WO1993005025A1 (en) | C-linked pyrazole derivatives | |
| JPWO2023049886A5 (https=) | ||
| JP2987339B2 (ja) | トリアゾール抗真菌性薬 | |
| JPWO2018098412A5 (https=) |